Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades,
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …

Context Treatment of metastatic urothelial carcinoma is currently undergoing a rapid
evolution. Objective This overview presents the updated European Association of Urology …

Urothelial carcinoma (UC), also described as bladder cancer, is the 10th most common
cancer type worldwide, with an estimated 549 000 new cases and 200 000 deaths in 2018 …

PURPOSE Locally advanced or metastatic urothelial carcinoma is an incurable disease with
limited treatment options, especially for patients who were previously treated with platinum …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder …

Purpose: To evaluate the efficacy and safety of RC48-ADC, a novel humanized anti-HER2
antibody conjugated with monomethyl auristatin E, in patients with HER2+ locally advanced …

Background First-line chemotherapy for patients with cisplatin-ineligible locally advanced or
metastatic urothelial carcinoma is associated with short response duration, poor survival …

Background Patients with metastatic urothelial carcinoma have a dismal prognosis and few
treatment options after first-line chemotherapy. Responses to second-line treatment are …

Background Few effective treatments exist for patients with advanced urothelial carcinoma
that has progressed after platinum-based chemotherapy. We assessed the activity and …

Context Invasive bladder cancer is a frequently occurring disease with a high mortality rate
despite optimal treatment. The European Association of Urology (EAU) Muscle-invasive and …